Addison Pierce

Addison advises investors, lenders and life sciences companies on structured financings, with a focus on royalty and revenue transactions. He represents public and private companies, private equity firms, banks and nonbank lenders in a range of financing and corporate matters. His practice spans the full spectrum of debt financing and capital markets transactions, including acquisition financings, secured and unsecured credit facilities, and high-yield and investment-grade bond offerings.

Addison’s representative matters include:

Lender-side engagements

• Blue Owl Capital in its:
  • $140 million royalty-backed debt financing provided to XOMA Corporation
  • $1.05 billion financing provided to BridgeBio Pharma, consisting of a $300 million royalty financing and a $450 million credit facility
  • Up to $262.5 million in term loans to ITM Isotope Technologies
  • Up to $250 million in term loans to TG Therapeutics
  • Up to $500 million in term loans to Madrigal Pharmaceuticals
• HealthCare Royalty in its up to $250 million in term loans to TG Therapeutics
• Sixth Street in its up to $910 million strategic investment in Blueprint Medicines, consisting of a $250 million royalty financing and an up to $660 million credit facility

Borrower-side engagements

• Geron Corporation in its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors
• Nuvation Bio in its up to $250 million in term loan and royalty financings with Sagard Healthcare Partners
• Dermavant Sciences in its $160 million revenue financing and $40 million term loan
• Cara Therapeutics in its $40 million royalty interest purchase and sale agreement with HealthCare Royalty Partners
• Reata Pharmaceuticals in its $275 million debt financing from funds managed by Pharmakon Advisors
• Clearside Biomedical in its $65 million royalty interest purchase and sale agreement with HealthCare Royalty Partners
• Mirum Pharmaceuticals in its $210 million financing arrangement with Oberland Capital Management
• Paratek Pharmaceuticals in its $60 million nonrecourse loan from R-Bridge Healthcare Investment Advisory, an affiliate of CBC Group
• Uber Technologies in its:
  • $4 billion investment grade bond offering
  • $1 billion aggregate principal amount of 7.5% senior notes due 2025
• BioMarin Pharmaceutical in its $600 million unsecured revolving credit facility
• Tempus AI in its $600 million acquisition of Ambry Genetics
• Sprout Social in its $140 million acquisition of Tagger Media
• NETSTREIT in its more than $1.5 billion in unsecured credit facilities